Rx Product News (November 2014)

Pharmacy TimesNovember 2014 Cough & Cold
Volume 80
Issue 11

Marketed by: BD Medical, a segment of BD (Becton, Dickinson and Company)

Indication: BD AutoShield Duo Pen Needle is now available through retail pharmacies for people with diabetes. It is the only pen needle with patented dual front- and back-end shields for convenience and safety before and after injecting. The technology conceals the needle, helping to alleviate preinjection anxiety while reducing the risk for accidental needle stick in patients who inject insulin or other diabetes drugs.

Dosage Form: Injection

For More Information: http://bd.com/autoshieldduo


Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc

Indication: The FDA has approved Jardiance (empagliflozin), a sodium-glucose cotransporter 2 inhibitor, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The recommended dose is 10 mg once daily, taken in the morning, with or without food. The dose may be increased to 25 mg once daily.

Dosage Form: Tablets: 10 and 25 mg

For More Information: http://www.jardiance.com


Marketed by: Biocompatibles UK Ltd

Indication: The FDA has approved Varithena (polidocanol injectable foam), a sclerosing agent, for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. Varithena is for intravenous use under ultrasound guidance only. Up to 5 mL per injection and 15 mL per treatment session can be used. Treatment sessions should be separated by a minimum of 5 days.

Dosage Form: Polidocanol solution: 180 mg/18 mL (10 mg/mL); must be activated before use

For More Information: http://www.varithena.com


Marketed by: GlaxoSmithKline

Indication: The FDA has approved Tanzeum (albiglutide), a glucagon-like peptide-1 receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tanzeum should be injected subcutaneously in the abdomen, thigh, or upper arm once weekly at any time of day, without regard to meals. The initial dose is 30 mg, and the dose can be increased to 50 mg once weekly if additional glycemic control is required.

Dosage Form: Injection: 30 or 50 mg

For More Information: http://www.tanzeum.com

Related Videos
© 2023 MJH Life Sciences

All rights reserved.